Research Labs | National Cancer Centre Singapore

Cellular & Molecular Research

The Division of Cellular & Molecular Research is focused on understanding the mechanistic basis of tumour development and treatment response; as well as the translation of bench-based findings to devise strategies to improve the early detection and treatment of cancers.

Medical Sciences

The Division of Medical Sciences has evolved in the last decade to one that is completely focused on the mission of translating biological discoveries into the clinic.

Clinical Trials & Epidemiological Sciences

The Division was conceived to provide support and to encourage clinical trials within NCCS.

Research News

NCCS and NTU Singapore-led Cancer Prevention Research Institute Launches Studies to Evaluate Multi-Cancer Early Detection Tests and Tackle Metabolic Dysfunction-Linked Cancers in Singapore

Announcements NCCS and NTU Singapore-led Cancer Prevention Research Institute Launches Studies to Evaluate Multi-Cancer Early Detection Tests and Tackle Metabolic Dysfunction-Linked Cancers in Singapore The Research Institute for Cancer Prevention, Screening and Early Detection (RISE), jointly led by the National Cancer Centre Singapore (NCCS) and Nanyang Technological University, Singapore (NTU Singapore), has announced the launch of two studies; one led by NCCS to evaluate multi-cancer early detection (MCED) tests and another led by the Lee Kong Chian School of Medicine (LKCMedicine) at NTU Singapore to develop targeted screening and prevention for metabolic dysfunction-linked cancers in Singapore.

13 May 2026 Read story

Patient Care Global trial shows novel treatment for triple-negative breast cancer nearly doubles survival A global, multicentre phase III trial, TROPION-Breast02, led by a senior medical oncologist and researcher from the National Cancer Centre Singapore, has demonstrated a significant breakthrough in improving the survival of patients with untreated, advanced triple negative breast cancer (TNBC) using the novel antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd).

15 Apr 2026 Read story

Research Study uncovers the mechanisms behind tumour suppressor BAP1 protein, highlighting new treatment strategies for aggressive cancers A team of scientists led by the National Cancer Centre Singapore (NCCS) and Duke-NUS Medical School (Duke-NUS) has found a new approach for treating some of the world's most aggressive cancers associated with BAP1 mutations.

02 Apr 2026 Read story

View All News